Antisense Therapeutics Limited, a biopharmaceutical drug discovery and development company, engages in the research and development of antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor targeting VLA-4 that has completed Phase IIa for the treatment of multiple sclerosis and asthma; and ATL1101, an antisense inhibitor of CD49d for the treatment of inflammation associated with duchenne muscular dystrophy. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.
Industry, Sector and Symbol
Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone61 3 9827 8999
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$586,788.00
Profitability
Miscellaneous
Employees8
Next Earnings DateN/A
OptionableNot Optionable
Antisense Therapeutics (ASX:ANP) Frequently Asked Questions
What is Antisense Therapeutics' stock symbol?
Antisense Therapeutics trades on the ASX under the ticker symbol "ANP."
How were Antisense Therapeutics' earnings last quarter?
Has Antisense Therapeutics been receiving favorable news coverage?
News headlines about ANP stock have trended negative on Sunday, according to InfoTrie. InfoTrie identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Antisense Therapeutics earned a media sentiment score of -2.0 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Antisense Therapeutics.
Who are some of Antisense Therapeutics' key competitors?
Some companies that are related to Antisense Therapeutics include Allergy Therapeutics (AGY), Vita Life Sciences (VLS), Recce Pharmaceuticals (RCE), Patrys (PAB), Avivagen (VIV), Futura Medical (FUM), Sareum (SAR), Cathay International (CTI), China Pharma (CPHI), NanoViricides (NNVC), N4 Pharma (N4P), Bayer (BAYN), HedgePath Pharmaceuticals (MAYNF), OTSUKA HOLDINGS/ADR (OTSKY) and Roche (SNYNF).
What other stocks do shareholders of Antisense Therapeutics own?
Who are Antisense Therapeutics' key executives?
Antisense Therapeutics' management team includes the folowing people:
- Mr. Mark Diamond, MD & CEO
- Mr. Phillip Allen Hains, CFO & Company Sec. (Age 60)
- Dr. George Tachas, Director of Drug Discovery & Patents
- Susan Turner, Fin. & Admin. Mang.
- Ms. Nuket Desem, Director of Clinical and Regulatory affairs
How big of a company is Antisense Therapeutics?
What is Antisense Therapeutics' official website?
How can I contact Antisense Therapeutics?
The company can be reached via phone at 61 3 9827 8999.
MarketBeat Community Rating for Antisense Therapeutics (ASX ANP)
MarketBeat's community ratings are surveys of what our community members think about Antisense Therapeutics and other stocks. Vote "Outperform" if you believe ANP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANP will underperform the S&P 500 over the long term. You may vote once every thirty days.
